^
Association details:
| Biomarker: | HLA-A*24:02 |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Libtayo (cemiplimab-rwlc) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
690 Correlates of poor response to neoadjuvant anti-PD-1 therapy in hepatocellular carcinoma (HCC) include WNT pathway activation and loss of HLA expression
Published date:
11/08/2022
Excerpt:
In a neoadjuvant Phase 2 study (NCT03916627), patients with resectable hepatocellular carcinoma (HCC) were treated with cemiplimab...Clinical efficacy was associated with presence of HLA-A*24:02 allele (N=5; 4 Responders and 1 Non-responder).
DOI:
http://dx.doi.org/10.1136/jitc-2022-SITC2022.0690
Trial ID:
